First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
The company received seven observations in the Form-483
UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Subscribe To Our Newsletter & Stay Updated
